AZMATICS: AZithroMycin/Asthma: Trial in Community Settings

Study Description and Methods

This was a pilot randomized “practical clinical” that tested the hypothesis that azithromycin, an anti-chlamydial antibiotic treatment, would significantly improve asthma control. In the 12-month study, we examined the overall asthma symptoms, asthma medication use, quality of life, and exacerbations of approximately 600 older children and adults.

Specific Aims and Objectives

  1. Assess the impact of 12-week treatment with azithromycin on pre-specified patient-oriented asthma outcomes:
    1. Asthma symptoms
    2. Asthma rescue medication use
    3. Asthma quality of life (QOL)
    4. Asthma exacerbations
  2. Assess the impact of 12-week treatment with azithromycin on pre-specified asthma subgroups:
    1. Smoking
    2. Co-morbid respiratory conditions (diagnoses of “chronic asthmatic bronchitis” and “asthma with chronic airways obstruction”)

Timeline

This study was conducted between April 2006 and August 2008.

Contact Information

For additional information about this study, please contact:

Debbie Graham, MSPH
Senior Scientist
AAFP National Research Network
1-800-274-2237 x3120
dgraham@aafp.org

Key Findings and Publications

Adults with asthma who were randomized to azithromycin did not show statistically significant improvement in asthma outcomes, although the study was underpowered to detect clinical improvement in 15%. Adults with severe persistent asthma who elected OL treatment documented clinical improvements in asthma symptoms, AQL, and asthma control that persisted after completion of OL azithromycin.

Access the complete manuscript:

AZMATICS Study(18 page PDF) -- Hahn DL, Grasmick M, Hetzel S, et al, and on behalf of the AZMATICS Study Group. Azithromycin for Bronchial Asthma in Adults: An Effectiveness Trial. J Am Board Fam Med. 2012;25(4):442-459.
(PDF 18 pages)


This project was funded by grants from American Academy of Family Physicians Foundation, Wisconsin Academy of Family Physicians and Pfizer (for in-kind supply of study drug).